Evidence on the efficacy of adding macrolides (azithromycin or clarithromycin) to the treatment regimen for COVID-19 is limited. We testify whether adding azithromycin or clarithromycin to a standard of care regimen was superior to standard of supportive care alone in patients with mild COVID-19.This randomized trial included three groups of patients with COVID-19. The azithromycin group included, 107 patients who received azithromycin 500 mg/24 h for 7 days, the clarithromycin group included 99 patients who received clarithromycin 500 /12 h for 7 days, and the control group included 99 patients who received standard care only. All three groups received only symptomatic treatment for control of fever and cough .Clinical and biochemical evaluations of the study participants including assessment of the symptoms duration, real-time reverse transcription-polymerase chain reaction (rRT-PCR), C-reactive protein (CRP), serum ferritin, D-dimer, complete blood count (CBC), in addition to non-contrast chest computed tomography (CT), were performed. The overall results revealed significant early improvement of symptoms (fever, dyspnea and cough) in patients treated with either azithromycin or clarithromycin compared to control group, also there was significant early conversion of SARS-CoV-2 PCR to negative in patients treated with either azithromycin or clarithromycin compared to control group (p < 0.05 for all).There was no significant difference in time to improvement of fever, cough, dyspnea, anosmia, gastrointestinal tract "GIT" symptoms and time to PCR negative conversion between patients treated with azithromycin compared to patients treated with clarithromycin (p > 0.05 for all). Follow up chest CT done after 2 weeks of start of treatment showed significant improvement in patients treated with either azithromycin or clarithromycin compared to control group (p < 0.05 for all).Adding Clarithromycin or azithromycin to the therapeutic protocols for COVID-19 could be beneficial for early control of fever and early PCR negative conversion in Mild COVID-19.Trial registration: (NCT04622891) www.ClinicalTrials.gov retrospectively registered (November 10, 2020).

Evidence on the efficacy of adding macrolides (azithromycin or clarithromycin) to the treatment regimen for COVID-19 is limited. We testify whether adding azithromycin or clarithromycin to a standard of care regimen was superior to standard of supportive care alone in patients with mild COVID-19.The study included three groups of patients with COVID-19. The azithromycin group included, 107 patients who received azithromycin 500 mg/24 h for 7 days, the clarithromycin group included 99 patients who received clarithromycin 500 /12 h for 7 days, and the control group included 99 patients who received standard care only. All three groups received only symptomatic treatment for control of fever and cough .Clinical and laboratory evaluations of the study participants including assessment of the symptoms duration, real-time reverse transcription-polymerase chain reaction (rRT-PCR), C-reactive protein (CRP), serum ferritin, D-dimer, complete blood count (CBC), non-contrast chest computed tomography (CT), were performed.The overall results revealed significant early improvement of symptoms (fever, dyspnea and cough) in patients treated with either azithromycin or clarithromycin compared to control group, also there was significant early conversion of SARS-CoV-2 PCR to negative in patients treated with either azithromycin or clarithromycin compared to control group (p˂0.05 for all).There was no significant difference in time to improvement of fever, cough, dyspnea, anosmia, GIT symptoms and time to PCR negative conversion between patients treated with azithromycin compared to patients treated with clarithromycin (p˃0.05 for all). Follow up chest CT done after 2 weeks of start of treatment showed significant improvement in patients treated with either azithromycin or clarithromycin compared to control group (p˂0.05 for all).Adding Clarithromycin or Azithromycin to the therapeutic protocols for COVID-19 could be beneficial for early control of fever and early PCR negative conversion in Mild COVID-19

Background: After a tonsillectomy, the bared tonsillar fossa becomes colonised by the oral bacterial flora, which can cause a strong localised inflammatory reaction, pain aggravation, and a delay in healing. The present study aimed to evaluate and compare the effect of antibiotics given orally or intravenously with no antibiotic protocol on post-bipolar diathermy tonsillectomy morbidity. Patients and methods: From January 2021 to January 2022, a total of 300 patients indicated for tonsillectomy. Those patients were divided into three equal groups. Group I received injectable antibiotic in the first two days' post-operative followed by oral amoxicillin clavulanic acid for another 5 days. Group II received oral antibiotic (amoxicillin clavulanic acid 7 days postoperative. Group III didn't receive antibiotic postoperative period. Results: Vomiting and secondary diarrhoea were observed in high frequency in patients who received oral antibiotic (group II). Other data included fever, pain score and return to normal diet and normal activity showed no significant differences between the different groups. Conclusion:Based on the current study, there is no effect of antibiotics use on speed of recovery and pain score. New multi-center clinical trials are warranted to confirm such findings.

No abstract

No abstract